News|Articles|January 22, 2024

Migraine-Related Stigma Common, Leads to Greater Disability, Intellectual Burden, Reduced Quality of Life

Author(s)Marco Meglio

Using the validated Migraine-Related Stigma questionnaire, investigators observed significant between-group differences in disability, interictal burden, and quality of life based on the amount of migraine-related stigma experienced.

Published data from the OVERCOME study, an observational population-based examination of nearly 60,000 adults with migraine, showed that almost one-third of patients experienced migraine-related stigma often/very often. After controlling for sociodemographic, clinical characteristics, and monthly headache days, the study also found that experiencing migraine-related stigma often was associated with increased disability and interictal burden and reduced quality of life.

The study, comprised of 59,001 patients with migraine, used the 12-item Migraine-Related Stigma (MiRS) questionnaire to assess the frequency of migraine-related stigma. It contained 2 factors: feeling that others viewed migraine as being used for Secondary Gain (8 items; α = 0.92) and feeling that others were Minimizing disease Burden (4 items, α = 0.86). Because both MiRS-Secondary Gain scores (range 0–32) and MiRS-Minimizing Burden (range 0–16) had 0-inflated distributions, scores were categorized by how often the respondent experienced each aspect of migraine-related stigma.

Led by Robert Shapiro, MD, PhD, professor of neurology, University of Vermont Larner College of Medicine, patients were categorized as either (1) MiRS-Both (Secondary Gain and Minimizing Burden often/very often; (2) MiRS-SG (Secondary Gain often/very often); (3) MiRS-MB (Minimizing Burden often/very often); (4) MiRS-Rarely/Sometimes; (5) MiRS-Never. The current analyses focused on pooled data from baseline surveys conducted in 2018, 2019, and 2020.

READ MORE: FDA Issues Complete Response Letter for Satsuma’s DHE Nasal Powder STS101 to Treat Acute Migraine

In the sample, 31.7% (18,708 of 59,001) of patients reported experiencing MiRS-Secondary Gain and/or MiRS-Minimizing Burden often/very often. Experiences of at least 1 form of migraine-related stigma was found in 25.4% of those with 0-3 monthly headache days and 47.5% of those with at least 15 monthly headache days.

Between the groups, those who reported MiRS-MB, MiRS-SG, or MiRS-Both often/very often had more severe migraine-related disability (44.2% vs 9.9%; standardized mean difference [SMD], 0.84), as demonstrated by the Migraine Disability Assessment (MIDAS), and higher interictal burden (62.0% vs 11.2%; SMD, 1.24), as explained on Migraine Interictal Burden Scale (MIBS). In addition, these groups reported lower quality of life (MSQ-RFR, 41.2 vs 68.7; SMD, 1.2) more comorbidities (4.6 vs 3.0; SMD, 0.52), and higher Patient Health Questionnaire (PHQ)-4 scores (6.1 vs 2.6; SMD, 1.0).

When examining the relationship of MIDAS scores to MiRS, 74.9% of the MiRS-Both group had moderate or severe disability compared with just 18.6% of the MiRS-Never group. At each monthly headache day, the highest estimated MIDAS score was within the MiRS-Both group and lowest was within the MiRS-Never group.

Between the groups, a higher percentage of patients experiencing MiRS often/very often experienced interictal burden. More specifically, 79.4% of those in the MiRS-Both group had severe interictal burden vs 11.2% of those in the MiRS-Never group. Even after accounting for sociodemographics, clinical characteristics, and monthly headache day frequency associated with MIBS-4 total score, the risk of increased burden of migraine between attacks was significant for each MiRS group compared with the MiRS-Never group, and the risk more than tripled for the MiRS-Both group (RR, 3.55; 95% CI, 3.41-3.70).

REFERENCE
1. Shapiro RE, Nicholson RA, Seng EK, et al. Migraine-related stigma and its relationship to disability, interictal burden, and quality of life: results of the OVERCOME (US) study. Neurology. 2024;102(3). doi:10.1212/WNL.0000000000000208074

Related to this article

Brain Chat: Migraine: More Than Just a Headache
Mitzi Joi Williams, MD, is joined by Temitope Adeola, MD, and Chantale Branson, MD, to discuss migraine as a complex neurological condition, including recognizing symptoms and triggers, navigating acute and preventive treatment options, and incorporating lifestyle modifications to improve migraine management.
Collective Advocacy, Shared Priorities, and What’s Ahead at MDA 2027
Paul Melmeyer, MPP, Executive Vice President of Public Policy and Advocacy at the Muscular Dystrophy Association, discusses the Neuromuscular Advocacy Collaborative, its growing year-round presence, and what the group hopes to accomplish heading into the 2027 MDA Clinical and Scientific Conference.